R-CHOP 14方案联合或不联合放疗治疗非大肿块局限期弥漫大B细胞淋巴瘤
这项随机试验纳入非大肿块局限期弥漫大B细胞淋巴瘤患者,比较4或6周期R-CHOP(每2周一次)后是否加用40 Gy放疗。中位随访64个月,5年无事件生存率R-CHOP组89%±2.9% vs R-CHOP联合放疗组92%±2.4%(HR 0.61,95%CI 0.3-1.2,P=0.18),总生存两组亦无显著差异。
要点
- 非大肿块局限期DLBCL患者中,单纯R-CHOP不劣于R-CHOP后联合放疗。
- 5年EFS:R-CHOP组89%±2.9% vs 联合放疗组92%±2.4%(HR 0.61,95%CI 0.3-1.2,P=0.18)。
- 总生存两组无显著差异:R-CHOP组92%(95%CI 89.5%-94.5%)vs 联合放疗组96%(95%CI 94.3%-97.7%)。
核心结论
- 在非大肿块局限期弥漫大B细胞淋巴瘤患者中,单纯R-CHOP不劣于R-CHOP后联合放疗。
研究设计与样本
- 随机试验,纳入非大肿块局限期弥漫大B细胞淋巴瘤患者,按修改版国际预后指数(包括乳酸脱氢酶、美国东部肿瘤协作组体能状态、年龄和疾病分期)分层。
- 患者接受4或6个连续周期的R-CHOP(每2周一次),随后或不随后接受放疗(40 Gy,末次R-CHOP周期后4周给予)。
- 共随机分配165例至R-CHOP组,169例至R-CHOP联合放疗组;主要终点为从随机化开始的无事件生存期(EFS)。
主要发现
- 中位随访64个月,意向性治疗分析显示5年EFS在两组间无统计学显著差异:R-CHOP组89%±2.9% vs R-CHOP联合放疗组92%±2.4%(风险比0.61;95%CI 0.3-1.2;P=0.18)。
- 总生存两组亦无差异:R-CHOP组92%(95%CI 89.5%-94.5%)vs R-CHOP联合放疗组96%(95%CI 94.3%-97.7%)(P=无显著差异)。
关键数值与推荐
- 5年EFS:R-CHOP组89%±2.9% vs R-CHOP联合放疗组92%±2.4%(HR 0.61;95%CI 0.3-1.2;P=0.18)。
- 总生存:R-CHOP组92%(95%CI 89.5%-94.5%)vs R-CHOP联合放疗组96%(95%CI 94.3%-97.7%)(P=无显著差异)。
- 放疗剂量为40 Gy,于末次R-CHOP周期后4周给予。
临床怎么用
- 原文结论为在非大肿块局限期DLBCL患者中单纯R-CHOP不劣于R-CHOP后联合放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with nonbulky limited-stage DLBCL to evaluate the benefit of RT after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Patients were stratified according to the modified International Prognostic Index, including lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, age, and disease stage. The patients received 4 or 6 consecutive cycles of R-CHOP delivered once every 2 weeks, followed or not by RT at 40 Gy delivered 4 weeks after the last R-CHOP cycle. All patients were evaluated by fluorodeoxyglucose-positron emission tomography scans performed at baseline, after 4 cycles of R-CHOP, and at the end of treatment. The primary objective of the trial was event-free survival (EFS) from randomization. The trial randomly assigned 165 patients in the R-CHOP arm and 169 in the R-CHOP plus RT arm. In an intent-to-treat analysis with a median follow-up of 64 months, 5-year EFS was not statistically significantly different between the 2 arms, with 89% ± 2.9% in the R-CHOP arm vs 92% ± 2.4% in the R-CHOP plus RT arm (hazard ratio, 0.61; 95% confidence interval [CI], 0.3-1.2; P = .18). Overall survival was also not different at 92% (95% CI, 89.5%-94.5%) for patients assigned to R-CHOP alone and 96% (95% CI, 94.3%-97.7%) for those assigned to R-CHOP plus RT (P = not significant). R-CHOP alone is not inferior to R-CHOP followed by RT in patients with nonbulky limited-stage DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT00841945.
引用
- Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2017. PMID: 29061568. doi:10.1182/blood-2017-07-793984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。